{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:36:16Z","timestamp":1789202176827,"version":"build-2803163510"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2020,6,1]]},"DOI":"10.1001\/jamainternmed.2020.1097","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T15:50:40Z","timestamp":1588002640000},"page":"912","source":"Crossref","is-referenced-by-count":108,"title":["FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019"],"prefix":"10.1001","volume":"180","author":[{"given":"Emerson Y.","family":"Chen","sequence":"first","affiliation":[{"name":"Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland"},{"name":"Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"ild200014r1","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals.","volume":"175","author":"Kim","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"6","key":"ild200014r2","first-page":"91","article-title":"Strength of validation for surrogate end points used in the US Food and Drug Administration\u2019s approval of oncology drugs.","author":"Kim","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"ild200014r3","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the clinical benefit of cancer drugs receiving accelerated approval.","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"5","key":"ild200014r4","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/jamainternmed.2018.8351","article-title":"Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials.","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern Med"},{"key":"ild200014r5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12918-017-0464-7","article-title":"A systematic analysis of FDA-approved anticancer drugs.","volume":"11","author":"Sun","year":"2017","journal-title":"BMC Syst Biol"},{"key":"ild200014r6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejca.2018.11.012","article-title":"A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology.","volume":"106","author":"Haslam","year":"2019","journal-title":"Eur J Cancer"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2764287\/jamainternal_chen_2020_ld_200014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T11:02:58Z","timestamp":1591009378000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2764287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":6,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2020.1097","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,1]]}}}